GINA Management for Suspected Asthma in Adults
For adults with suspected asthma, you must first confirm the diagnosis objectively with spirometry or peak flow testing before initiating treatment, then start all patients on ICS-containing therapy—never SABA alone—using either Track 1 (preferred: as-needed low-dose ICS-formoterol) or Track 2 (alternative: regular ICS plus as-needed SABA). 1, 2, 3, 4
Diagnostic Confirmation
Before treating suspected asthma, objective confirmation is mandatory 1. The 2024 GINA report specifies five methods to confirm excessive variability in lung function:
- Positive bronchodilator reversibility test: FEV1 improvement ≥12% and ≥200 mL from baseline after inhaled bronchodilator
- Excessive PEF variability: >10% diurnal variation over 2 weeks
- Lung function improvement: After 4 weeks of ICS treatment
- Positive bronchial challenge test: Demonstrating airway hyperresponsiveness
- Excessive variation between visits: Significant lung function fluctuation over time
Critical pitfall: Do not diagnose asthma on symptoms alone, especially in elderly patients or smokers with wheeze, as COPD and other conditions can mimic asthma 5, 1. If patients are already on ICS-containing medications, repeat objective testing and consider a trial step-down to unmask reversibility 1.
Initial Treatment Algorithm
Track 1 (Preferred Approach)
All treatment steps use as-needed low-dose ICS-formoterol as the reliever 2, 3, 4:
- Step 1-2 (Mild asthma): As-needed ICS-formoterol only
- Step 3-5 (Moderate-severe): Daily maintenance ICS-formoterol PLUS as-needed ICS-formoterol (MART regimen)
This approach reduces severe exacerbations by ≥60% compared to SABA alone in mild asthma, with equivalent symptom control and lung function outcomes as daily ICS plus as-needed SABA 4.
Track 2 (Alternative Approach)
Uses as-needed SABA as reliever across all steps 2, 3:
- Step 2: Regular low-dose ICS + as-needed SABA
- Step 3-5: Regular ICS-LABA + as-needed SABA
Why Never SABA Alone
The evidence is unequivocal: SABA monotherapy increases the risk of severe exacerbations and asthma-related death 2, 3, 4. Even patients with infrequent symptoms (previously labeled "mild intermittent") require ICS-containing therapy to reduce exacerbation risk.
Stepwise Treatment Escalation
Step up therapy when:
- SABA use >2 days/week for symptom relief (not exercise prevention)
- Nocturnal symptoms present
- Any activity limitation
- Peak flow <80% personal best
- Any exacerbation requiring systemic corticosteroids 6, 7
Step down therapy when:
- Well-controlled for ≥3 consecutive months
- Low exacerbation risk
- Patient preference for minimal medication 6, 7, 4
Self-Management Plan Components
Every patient requires a written asthma action plan with three elements 5, 2:
- Monitoring: Symptoms, peak flow, medication usage
- Prearranged actions:
- Increase ICS when symptoms worsen
- Self-administer oral corticosteroids when PEF falls below agreed threshold (typically <60% personal best)
- Seek urgent medical attention when treatment fails
- Written guidance: Specific to individual thresholds
Specialist Referral Indications
Refer to respiratory physician when 5:
- Diagnostic uncertainty: Elderly patients, smokers with wheeze, unexplained systemic symptoms (fever, rash, weight loss, proteinuria suggesting vasculitis or eosinophilia)
- Occupational asthma suspected
- Management problems:
Acute Exacerbation Recognition
Severe asthma features requiring immediate treatment 5:
- Cannot complete sentences in one breath
- Respiratory rate >25/min
- Heart rate >110/min
- PEF <50% predicted or personal best
Life-threatening features:
- PEF <33% predicted
- Silent chest, cyanosis, feeble respiratory effort
- Bradycardia, hypotension
- Exhaustion, confusion, coma
- Normal or elevated PaCO2 in breathless patient
Immediate management: High-dose inhaled β-agonist (salbutamol 5 mg nebulized or 10-20 puffs via spacer) + oral prednisolone 30-60 mg or IV hydrocortisone 200 mg 5.
Key Clinical Pearls
- Inhaler technique must be verified at every visit—poor technique is a major cause of apparent treatment failure 5
- Smoking cessation is mandatory—counsel at every visit 8
- Avoid allergen triggers when identified (house dust mite, pets, pollens) 8
- Monitor for ICS side effects at doses >400 µg/day (growth in children, bone density in adults on long-term therapy) 5
- Oral corticosteroid courses (30-40 mg prednisolone) do not require tapering when used <2 weeks 8
The evidence strongly supports that modern asthma management prioritizes ICS-containing therapy from diagnosis, individualized assessment with objective monitoring, and proactive self-management education to prevent exacerbations and asthma-related mortality 2, 3, 4.